{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:08:55Z","timestamp":1792825735968,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.cgh.2017.05.014","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:18:48Z","timestamp":1495153128000},"page":"1338-1349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":168,"title":["Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits"],"prefix":"10.1016","volume":"15","author":[{"given":"Michael","family":"Camilleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Katzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2017.05.014_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1533-2500.2008.00222.x","article-title":"The fifth vital sign: what does it mean?","volume":"8","author":"Walid","year":"2008","journal-title":"Pain Pract"},{"key":"10.1016\/j.cgh.2017.05.014_bib2","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1111\/j.1526-4637.2009.00666.x","article-title":"Long-acting opioids and short-acting opioids: appropriate use in chronic pain management","volume":"10","author":"Fine","year":"2009","journal-title":"Pain Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib3","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.1995.03530230056031","article-title":"The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation","volume":"274","author":"Jadad","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2017.05.014_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0304-3959(98)00117-1","article-title":"Prevalence of chronic benign pain disorder among adults: a review of the literature","volume":"77","author":"Verhaak","year":"1998","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/j.pain.0000000000000314","article-title":"A\u00a0systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population","volume":"157","author":"Mansfield","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","article-title":"Opioids in chronic non-cancer pain: systematic review of efficacy and safety","volume":"112","author":"Kalso","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (Probe 1)","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib8","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ajg.2009.71","article-title":"Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study","volume":"104","author":"Choung","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib9","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.cgh.2017.05.014_bib10","unstructured":"Available at: http:\/\/www.cdc.gov\/homeandrecreationalsafety\/pdf\/Common_Elements_in_Guidelines_for_Prescribing_Opioids-a.pdf. Accessed January 31, 2017."},{"key":"10.1016\/j.cgh.2017.05.014_bib11","unstructured":"Available at: http:\/\/www.cdc.gov\/primarycare\/materials\/opoidabuse\/docs\/pdaphperspective508.pdf. Accessed January 31, 2017."},{"key":"10.1016\/j.cgh.2017.05.014_bib12","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMp1612578","article-title":"Ending the opioid epidemic: a call to action","volume":"375","author":"Murthy","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib13","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMp1011512","article-title":"A\u00a0flood of opioids, a rising tide of deaths","volume":"363","author":"Okie","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/pr.112.005942","article-title":"Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.cgh.2017.05.014_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-5793(95)01185-H","article-title":"On the role of extracellular loops of opioid receptors in conferring ligand selectivity","volume":"375","author":"Metzger","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cgh.2017.05.014_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2174\/1568026053544579","article-title":"The function of the extracellular regions in opioid receptor binding: insights from computational biology","volume":"5","author":"Paterlini","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.cgh.2017.05.014_bib17","doi-asserted-by":"crossref","first-page":"E126","DOI":"10.1208\/aapsj080115","article-title":"Molecular recognition of opioid receptor ligands","volume":"8","author":"Kane","year":"2006","journal-title":"AAPS J"},{"key":"10.1016\/j.cgh.2017.05.014_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ajgsup.2014.5","article-title":"Molecular physiology of enteric opioid receptors","volume":"2","author":"Galligan","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003495-200363070-00003","article-title":"Opioid-induced bowel dysfunction: pathophysiology and potential new therapies","volume":"63","author":"Kurz","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.cgh.2017.05.014_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0166-2236(00)01611-8","article-title":"Endogenous morphine","volume":"23","author":"Stefano","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.cgh.2017.05.014_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199302000-00001","article-title":"Pharmacological mechanisms of opioid analgesics","volume":"16","author":"Pasternak","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.cgh.2017.05.014_bib22","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(24)36704-7","article-title":"Human pharmacology of the opioid neuropeptide dynorphin A (1-13)","volume":"281","author":"Greenwald","year":"1997","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00213-010-1819-6","article-title":"Kappa opioids and the modulation of pain","volume":"210","author":"Kivell","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.cgh.2017.05.014_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drugalcdep.2006.04.001","article-title":"Pattern of use and subjective effects of Salvia divinorum among recreational users","volume":"85","author":"Gonzalez","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.cgh.2017.05.014_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0306-4522(97)00227-3","article-title":"Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract","volume":"81","author":"Bagnol","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.cgh.2017.05.014_bib26","first-page":"G147","article-title":"Dose-related effects of synthetic human beta-endorphin and naloxone of fed gastrointestinal motility","volume":"251","author":"Camilleri","year":"1986","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cgh.2017.05.014_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00004836-199212000-00011","article-title":"The effect of loperamide on anorectal function in normal healthy men","volume":"15","author":"Musial","year":"1992","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib28","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/BF01303214","article-title":"Effects of morphine and naloxone on esophageal motility and gastric emptying in man","volume":"31","author":"Mittal","year":"1986","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.05.014_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gut.34.1.16","article-title":"Lower oesophageal sphincter hypersensitivity to opioid receptor stimulation in patients with idiopathic achalasia","volume":"34","author":"Penagini","year":"1993","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.05.014_bib30","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0002-9610(01)00782-6","article-title":"Incidence, prevalence, and management of opioid bowel dysfunction","volume":"182","author":"Pappagallo","year":"2001","journal-title":"Am J Surg"},{"key":"10.1016\/j.cgh.2017.05.014_bib31","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fphar.2014.00280","article-title":"Opioid receptor densensitization: mechanisms and its link to tolerance","volume":"5","author":"Allouche","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cgh.2017.05.014_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0165-6147(00)01616-3","article-title":"Incomplete cross tolerance and multiple mu opioid peptide receptors","volume":"22","author":"Pasternak","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cgh.2017.05.014_bib33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1089\/dna.2005.24.736","article-title":"Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters","volume":"24","author":"Pan","year":"2005","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.cgh.2017.05.014_bib34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/0024-3205(89)90272-5","article-title":"Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model","volume":"45","author":"Ling","year":"1989","journal-title":"Life Sci"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2017.05.014_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1743-3150.2004.00554.x","article-title":"Function of opioids in the enteric nervous system","author":"Wood","year":"2004","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2017.05.014_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0301-0082(01)00023-5","article-title":"Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and \u00df-arrestin proteins","volume":"66","author":"Claing","year":"2002","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.cgh.2017.05.014_bib37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/gast.1997.v113.pm9247457","article-title":"Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation","volume":"113","author":"Penagini","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.05.014_bib38","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2036.2009.04212.x","article-title":"Opiate-induced oesophageal dysmotility","volume":"31","author":"Kraichely","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ajg.2015.154","article-title":"Opioid-induced esophageal dysfunction (OIED) in patients on chronic opioids","volume":"110","author":"Ratuapli","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/dote.12291","article-title":"Achalasia and chronic opiate use: innocent bystanders or associated conditions?","volume":"29","author":"Ravi","year":"2016","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.cgh.2017.05.014_bib41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/00000542-199207000-00023","article-title":"Postoperative nausea and vomiting: its etiology, treatment, and prevention","volume":"77","author":"Watcha","year":"1992","journal-title":"Anesthesiology"},{"key":"10.1016\/j.cgh.2017.05.014_bib42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0022-3565(25)31039-6","article-title":"Naloxone antagonizes narcotic self blockade of emesis in the cat","volume":"203","author":"Costello","year":"1977","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3940(00)01113-7","article-title":"The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis","volume":"286","author":"Ariumi","year":"2000","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.cgh.2017.05.014_bib44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1369-1600.2011.00419.x","article-title":"Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers","volume":"18","author":"Walsh","year":"2013","journal-title":"Addict Biol"},{"key":"10.1016\/j.cgh.2017.05.014_bib45","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0149-2918(00)80024-7","article-title":"Intravenous ondansetron for the control of opioid-induced nausea and vomiting","volume":"21","author":"Sussman","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib46","first-page":"179","article-title":"Evaluation of the effective drugs for the prevention of nausea and vomiting induced by morphine used for postoperative pain: a quantitative systematic review","volume":"121","author":"Hirayama","year":"2001","journal-title":"J\u00a0Pharm Soc Jpn"},{"key":"10.1016\/j.cgh.2017.05.014_bib47","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2346.1999.00547.x","article-title":"Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients","volume":"16","author":"Chung","year":"1999","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.cgh.2017.05.014_bib48","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1365-2346.1999.00561.x","article-title":"An assessment of prochlorperazine buccal for the prevention of nausea and vomiting during intravenous patient-controlled analgesia with morphine following abdominal hysterectomy","volume":"16","author":"Williams","year":"1999","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.cgh.2017.05.014_bib49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1053\/j.gastro.2010.10.015","article-title":"Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity","volume":"140","author":"Parkman","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.05.014_bib50","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/nmo.12091","article-title":"Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting","volume":"25","author":"Hasler","year":"2013","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2017.05.014_bib51","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1365-2036.2012.05040.x","article-title":"A\u00a0randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans","volume":"35","author":"Jeong","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib52","first-page":"818","article-title":"Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy","volume":"37","author":"Maurer","year":"1996","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib53","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ejpain.2005.10.002","article-title":"Interaction between tramadol and two anti-emetics on nociception and gastrointestinal transit in mice","volume":"10","author":"D\u00fcrsteler","year":"2006","journal-title":"Eur J Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib54","first-page":"G572","article-title":"Control mechanism of spontaneous in\u00a0vitro contractions of the opossum sphincter of Oddi","volume":"249","author":"Helm","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cgh.2017.05.014_bib55","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/gut.29.10.1402","article-title":"Effects of morphine on the human sphincter of Oddi","volume":"29","author":"Helm","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.05.014_bib56","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1572-0241.2001.03536.x","article-title":"Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis","volume":"96","author":"Donald","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0016-5107(96)70158-X","article-title":"Effects of meperidine on the pancreatic and biliary sphincter","volume":"44","author":"Sherman","year":"1996","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cgh.2017.05.014_bib58","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib59","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ajg.2016.542","article-title":"Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea","volume":"112","author":"Cash","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/archsurg.138.2.206","article-title":"Mechanisms and treatment of postoperative ileus","volume":"138","author":"Luckey","year":"2003","journal-title":"Arch Surg"},{"key":"10.1016\/j.cgh.2017.05.014_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MCG.0000000000000246","article-title":"Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review","volume":"49","author":"Gaertner","year":"2015","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib62","article-title":"Bowel disorders","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.05.014_bib63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-3565(25)11008-2","article-title":"Peptide opioid antagonist separates peripheral and central opioid antitransit effects","volume":"243","author":"Shook","year":"1987","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0885-3924(02)00424-4","article-title":"Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation","volume":"24","author":"Choi","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.cgh.2017.05.014_bib65","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2982.2009.01458.x","article-title":"Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain","volume":"22","author":"Tuteja","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2017.05.014_bib66","first-page":"371","article-title":"Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation","volume":"12","author":"Rentz","year":"2009","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.cgh.2017.05.014_bib67","first-page":"41","article-title":"The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients","volume":"39","author":"Ueberall","year":"2011","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.cgh.2017.05.014_bib68","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/pme.12937","article-title":"Consensus recommendations on initiating prescription therapies for opioid-induced constipation","volume":"16","author":"Argoff","year":"2015","journal-title":"Pain Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib69","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cgh.2007.06.013","article-title":"The narcotic bowel syndrome: clinical features, pathophysiology, and management","volume":"5","author":"Grunkemeier","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.05.014_bib70","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrgastro.2014.53","article-title":"Diagnosis and treatment of narcotic bowel syndrome","volume":"11","author":"Kurlander","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.05.014_bib71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ajgsup.2014.6","article-title":"The narcotic bowel syndrome: a recent update","volume":"2","author":"Drossman","year":"2014","journal-title":"Am J Gastroenterol Suppl"},{"key":"10.1016\/j.cgh.2017.05.014_bib72","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2012.142","article-title":"Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome","volume":"107","author":"Drossman","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib73","article-title":"Opioid analgesic use among patients presenting with acute abdominal pain and factors associated with surgical diagnoses","author":"Khemani","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2017.05.014_bib74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01296258","article-title":"Role of loperamide and placebo in management of irritable bowel syndrome (IBS)","volume":"29","author":"Cann","year":"1984","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.05.014_bib75","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/gut.48.2.272","article-title":"Treatment of irritable bowel syndrome: a review of randomised controlled trials","volume":"48","author":"Akehurst","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.05.014_bib76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/00365529709025060","article-title":"Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence","volume":"32","author":"Sun","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib77","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365528709091003","article-title":"Loperamide in treatment of irritable bowel syndrome: a double-blind placebo controlled study","volume":"130","author":"Lav\u00f6","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.cgh.2017.05.014_bib78","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","article-title":"Loperamide treatment of the irritable bowel syndrome","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.cgh.2017.05.014_bib79","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/ajg.2011.78","article-title":"Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria","volume":"106","author":"Hellstr\u00f6m","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib80","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.05.014_bib81","unstructured":"FDA Adverse Event Reporting System detailed report from 2 Jan 2016 to 18 Oct 2016 under Freedom of Information Act. Eluxadoline\/Viberzi. Issued 21 October\u00a02016."},{"key":"10.1016\/j.cgh.2017.05.014_bib82","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jss.2016.01.027","article-title":"Alvimopan combined with enhanced recovery strategy for managing postoperative ileus after open abdominal surgery: a systematic review and meta-analysis","volume":"203","author":"Xu","year":"2016","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.cgh.2017.05.014_bib83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0885-3924(01)00369-4","article-title":"Low-dose oral naloxone reverses opioid-induced constipation and analgesia","volume":"23","author":"Liu","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.cgh.2017.05.014_bib84","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0304-3959(99)00185-2","article-title":"Oral naloxone reverses opioid-associated constipation","volume":"84","author":"Meissner","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib85","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/13543784.2011.563236","article-title":"Naloxone as part of a prolonged release oxycodone\/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers","volume":"20","author":"Smith","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cgh.2017.05.014_bib86","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpain.2008.06.012","article-title":"A\u00a0randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation","volume":"13","author":"Meissner","year":"2009","journal-title":"Eur J Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib87","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-014-0177-9","article-title":"Oxycodone\/naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation","volume":"74","author":"Burness","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.cgh.2017.05.014_bib88","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14656560902796798","article-title":"Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial","volume":"10","author":"Lowenstein","year":"2009","journal-title":"Exp Opin Pharmacother"},{"key":"10.1016\/j.cgh.2017.05.014_bib89","doi-asserted-by":"crossref","first-page":"415","DOI":"10.36076\/ppj.2014\/17\/415","article-title":"Effect of a fixed-dose opioid agonist\/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives","volume":"17","author":"Mehta","year":"2014","journal-title":"Pain Physician"},{"key":"10.1016\/j.cgh.2017.05.014_bib90","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.clinthera.2015.02.010","article-title":"Treatment with prolonged-release oxycodone\/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation","volume":"37","author":"Poelaert","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib91","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1742-1241.2010.02360.x","article-title":"Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain","volume":"64","author":"Sandner-Kiesling","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cgh.2017.05.014_bib92","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejpain.2010.06.017","article-title":"Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?","volume":"14","author":"Kress","year":"2010","journal-title":"Eur J Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib93","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pain.2010.10.004","article-title":"Mu-opioid and noradrenergic \u03b1(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats","volume":"152","author":"Bee","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib94","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"Afilalo","year":"2010","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.cgh.2017.05.014_bib95","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.2010.497720","article-title":"Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study","volume":"11","author":"Buynak","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cgh.2017.05.014_bib96","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5737\/1181912x234236240","article-title":"Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review","volume":"23","author":"Ruston","year":"2013","journal-title":"Can Oncol Nurs J"},{"key":"10.1016\/j.cgh.2017.05.014_bib97","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cgh.2017.05.014_bib98","first-page":"67","article-title":"Laxative prescriptions to cancer outpatients receiving opioids: a study from the Norwegian prescription database","volume":"21","author":"Skollerud","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cgh.2017.05.014_bib99","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/acem.12745","article-title":"Constipation prophylaxis is rare for adults prescribed outpatient opioid therapy from U.S. emergency departments","volume":"22","author":"Hunold","year":"2015","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib100","first-page":"131","article-title":"Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose","volume":"21","author":"Wirz","year":"2012","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.cgh.2017.05.014_bib101","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/pme.12724","article-title":"Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: laxative use, response, and symptom burden over time","volume":"16","author":"Coyne","year":"2015","journal-title":"Pain Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib102","doi-asserted-by":"crossref","first-page":"C479","DOI":"10.1152\/ajpcell.00077.2014","article-title":"Differentiation between human Clc-2 and Cftr Cl- channels with pharmacological agents","volume":"307","author":"Cuppoletti","year":"2014","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.cgh.2017.05.014_bib103","doi-asserted-by":"crossref","first-page":"G942","DOI":"10.1152\/ajpgi.00264.2005","article-title":"Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in healthy volunteers","volume":"290","author":"Camilleri","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2017.05.014_bib104","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ajg.2015.106","article-title":"A\u00a0randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain","volume":"110","author":"Jamal","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.05.014_bib105","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/pme.12437","article-title":"A\u00a0randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain","volume":"15","author":"Cryer","year":"2014","journal-title":"Pain Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib106","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12013-012-9406-6","article-title":"Methadone but not morphine inhibits lubiprostone-stimulated Cl\u2212 currents in T84 intestinal cells and recombinant human Clc-2, but not Cftr Cl\u2212 currents","volume":"66","author":"Cuppoletti","year":"2013","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.cgh.2017.05.014_bib107","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0028-3908(85)90072-3","article-title":"The use of quaternary narcotic antagonists in opiate research","volume":"24","author":"Brown","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cgh.2017.05.014_bib108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neulet.2003.12.004","article-title":"Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans","volume":"361","author":"Holzer","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.cgh.2017.05.014_bib109","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1124\/jpet.300.1.118","article-title":"Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial","volume":"300","author":"Yuan","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib110","first-page":"554","article-title":"Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study","volume":"12","author":"Michna","year":"2011","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jval.2010.11.003","article-title":"Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms","volume":"14","author":"Iyer","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2017.05.014_bib112","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jpainsymman.2010.01.011","article-title":"Methylnaltrexone and gastrointestinal perforation","volume":"40","author":"Mackey","year":"2010","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.cgh.2017.05.014_bib113","first-page":"1210","article-title":"Evaluation of single oral doses of Nktr118 (Peg-Naloxol) as a peripheral opioid antagonist (Poa): a double-blind placebo-controlled study in healthy male subjects","volume":"47","author":"Neumann","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2017.05.014_bib114","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0378-5173(03)00372-7","article-title":"Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs","volume":"263","author":"Faassen","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.cgh.2017.05.014_bib115","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.pain.2013.04.024","article-title":"A\u00a0phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation","volume":"154","author":"Webster","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2017.05.014_bib116","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","article-title":"Naloxegol for opioid-induced constipation in patients with noncancer pain","volume":"370","author":"Chey","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2017.05.014_bib117","article-title":"Translating clinical findings into the patient's perspective: post-hoc pooled analysis of bowel movement changes as a predictor of improvement in patients' opioid-induced constipation symptoms and outcomes","author":"Coyne","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib118","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40273-016-0454-4","article-title":"Cost effectiveness of naloxegol for opioid-induced constipation in the UK","volume":"35","author":"Lawson","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.cgh.2017.05.014_bib119","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/apt.12899","article-title":"Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation","volume":"40","author":"Webster","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.05.014_bib120","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1185\/03007995.2014.971355","article-title":"Fixed ratio (2:1) prolonged-release oxycodone\/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives","volume":"11","author":"Koopmans","year":"2014","journal-title":"Curr Med Res Opin"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235651730589X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235651730589X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:22:55Z","timestamp":1761542575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235651730589X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":120,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S154235651730589X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2017.05.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727639364.793563985","asserted-by":"object"}]},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2017.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the AGA Institute","name":"copyright","label":"Copyright"}]}}